Updates are available Correction dated 2026-04-28
Click to view Correction: https://doi.org/10.1007/s00415-026-13792-3
-
Authors
Meucci, Luca https://orcid.org/0009-0009-7948-2746
Meyer, Lukas
Broocks, Gabriel
Bechstein, Matthias
Thaler, Christian
Heitkamp, Christian
Winkelmeier, Laurens
Geest, Vincent
Heitkamp, Alexander
Jungnitz, Maximilian
Peter, Gregor
Schlicht, Felix
Nawabi, Jawed
Brekenfeld, Caspar
Maros, Máté E.
Schell, Maximilian
Hanning, Uta
Thomalla, Götz
Fiehler, Jens
Gellißen, Susanne
Flottmann, Fabian
Kniep, Helge C.
,
Röther, Joachim
Eckert, Bernd
Braun, Michael
Hamann, Gerhard F.
Siebert, Eberhard
Nolte, Christian
Zweynert, Sarah
Bohner, Georg
Berrouschot, Jörg
Bormann, Albrecht
Kraemer, Christoffer
Leischner, Hannes
Hattingen, Jörg
Petersen, Martina
Stögbauer, Florian
Boeckh-Behrens, Tobias
Wunderlich, Silke
Ludolph, Alexander
Henn, Karl-Heinz
Gerloff, Christian
Alegiani, Anna
Reich, Arno
Nikoubashman, Omid
Dorn, Franziska
Petzold, Gabor
Liman, Jan
Schäfer, Jan Hendrik
Keil, Fee
Gröschel, Klaus
Uphaus, Timo
Schellinger, Peter
Borggrefe, Jan
Tiedt, Steffen
Kellert, Lars
Trumm, Christoph
Ernemann, Ulrike
Poli, Sven
Riedel, Christian
Ernst, Marielle Sophie
- License Information
-
More Information
Article History
Received: 30 July 2025
Revised: 17 September 2025
Accepted: 21 September 2025
First Online: 9 October 2025
Change Date: 10 April 2026
Change Type: Update
Change Details: The original online version of this article was revised: due to the one of the author name was incorrect in the article.
Change Date: 28 April 2026
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00415-026-13792-3
Declarations
:
: Helge Kniep, Fabian Flottmann, Laurens Winkelmeier and Máté Maros are consultants for Eppdata GmbH. Helge Kniep is shareholder of Eppdata GmbH. Götz Thomalla received fees as consultant from Acandis, Boehringer Ingelheim, Bayer, and Portola, and fees as lecturer from Acandis, Alexion, Amarin, Bayer, Boehringer-Ingelheim, BMS/Pfizer, Daiichii Sankyo and Portola. He serves in the board of the TEA Stroke Study and of ESO. Jens Fiehler is consultant for Cerenovus, Medtronic, Microvention, Penumbra, Phenox, Roche and Tonbridge. He serves in the advisory board of Stryker and Phenox. He is stockholder of Tegus Medical, Eppdata and Vastrax. He serves as Associate Editor at JNIS.
